Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Pneumagen, a UK-based spinout of University of St Andrews working on a nose spray to prevent and treat respiratory infections, has obtained £2.5m ($3.4m) in an extension backed by an undisclosed corporate and unnamed, existing investors. The company raised an initial $4.9m tranche in May 2020 from Thairm Bio and Scottish Investment Bank. Pneumagen has…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.